基于打破树突状细胞耐受的抗肿瘤免疫治疗  

Tumor immunotherapy based on breaking the tolerance of Dendritic cells

作　　者：赵晓鸿[1] 宁振飞[1] 杨荣存[1] 

机构地区：[1]南开大学医学院,天津300071

出　　处：《国际免疫学杂志》2008年第4期256-260,共5页International Journal of Immunology

基　　金：国家自然科学基金委项目（项目号：30540022）

摘　　要：树突状细胞（DC）是专职抗原呈递细胞，具有强大的免疫监视功能。由于在诱导免疫反应中的重要作用，DC已被广泛地应用于抗肿瘤免疫治疗。但是由于肿瘤细胞对荷瘤宿主免疫系统，尤其是对DC功能的抑制，使以DC为基础的抗肿瘤免疫治疗疗效受到了很大的限制。所以，通过调节DC功能，可打破肿瘤对DC的免疫抑制，引导有效的抗肿瘤反应，提高以DC为基础的抗肿瘤免疫效果，这在抗肿瘤免疫治疗中具有重要意义。Dendritic ceils （ DCs）, the most effective professional antigen presenting cells in the immune system, are able to induce and regulate different kinds of immune responses. Although DCs have been widely used in tumor immunotherapy, the DC - based therapies against tumors are Limited since their function and activity are often inhibited by tumor and/or tumor associated factors. Thus, importance significant if DC activity could be regulated to resist tumor - induced suppression. In this review, we summarize the current knowledge about the immune therapies by the means of breaking tumor induced suppression on DCs to enhance the clinical responses against cancer.

关 键 词：树突状细胞 免疫耐受 肿瘤免疫治疗 

分 类 号：R730[医药卫生—肿瘤]